Newron Pharmaceuticals S.p.A. (NP5.DE)
EUR 8.8
(-0.34%)
EUR 8.8
(-0.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -11.71 Million EUR | 10.32% |
| 2022 | -13.32 Million EUR | -13.32% |
| 2021 | -11.99 Million EUR | 31.49% |
| 2020 | -17.16 Million EUR | 11.47% |
| 2019 | -20.84 Million EUR | -29.95% |
| 2018 | -14.78 Million EUR | -188.62% |
| 2017 | -4.04 Million EUR | 65.64% |
| 2016 | -15.29 Million EUR | 36.66% |
| 2015 | -24.46 Million EUR | -112.35% |
| 2014 | -10.79 Million EUR | -44.53% |
| 2013 | -7.7 Million EUR | -219.98% |
| 2012 | -2.63 Million EUR | 61.81% |
| 2011 | -6.34 Million EUR | 70.54% |
| 2010 | -21.51 Million EUR | 10.57% |
| 2009 | -24.03 Million EUR | -33.16% |
| 2008 | -18.04 Million EUR | -33.31% |
| 2007 | -13.46 Million EUR | 19.19% |
| 2006 | -16.72 Million EUR | -11.12% |
| 2005 | -15.07 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -7.58 Million EUR | 0.0% |
| 2023 Q2 | -4.24 Million EUR | 0.0% |
| 2023 Q4 | -7.28 Million EUR | 0.0% |
| 2023 FY | - EUR | 10.32% |
| 2022 Q4 | -6.66 Million EUR | 0.0% |
| 2022 Q2 | -6.54 Million EUR | 0.0% |
| 2022 FY | - EUR | -13.32% |
| 2021 Q4 | -4.38 Million EUR | 0.0% |
| 2021 FY | - EUR | 31.49% |
| 2021 Q2 | -7.77 Million EUR | 0.0% |
| 2020 FY | - EUR | 11.47% |
| 2020 Q4 | -9.35 Million EUR | 0.0% |
| 2020 Q2 | -9.85 Million EUR | 0.0% |
| 2019 Q2 | -17.52 Million EUR | -263.46% |
| 2019 Q1 | -4.82 Million EUR | 33.79% |
| 2019 FY | - EUR | -29.95% |
| 2019 Q4 | -8.49 Million EUR | 0.0% |
| 2018 Q1 | -3.64 Million EUR | 43.06% |
| 2018 FY | - EUR | -188.62% |
| 2018 Q4 | -7.28 Million EUR | 0.0% |
| 2018 Q2 | -7.5 Million EUR | -105.72% |
| 2017 Q1 | -1.27 Million EUR | 80.21% |
| 2017 FY | - EUR | 65.64% |
| 2017 Q4 | -6.4 Million EUR | 0.0% |
| 2017 Q2 | 2.35 Million EUR | 285.19% |
| 2016 Q1 | -3.75 Million EUR | 65.12% |
| 2016 Q2 | -8.86 Million EUR | -135.68% |
| 2016 FY | - EUR | 36.66% |
| 2016 Q4 | -6.43 Million EUR | 0.0% |
| 2015 Q1 | -6.22 Million EUR | -44.57% |
| 2015 Q2 | -6.82 Million EUR | -9.6% |
| 2015 Q4 | -10.77 Million EUR | -73.06% |
| 2015 Q3 | -6.22 Million EUR | 8.76% |
| 2015 FY | - EUR | -112.35% |
| 2014 Q4 | -4.3 Million EUR | -61.2% |
| 2014 FY | - EUR | -44.53% |
| 2014 Q2 | -4.74 Million EUR | -77.7% |
| 2014 Q1 | -2.67 Million EUR | 18.1% |
| 2014 Q3 | -2.67 Million EUR | 43.72% |
| 2013 Q3 | -1.91 Million EUR | 19.69% |
| 2013 Q4 | -3.26 Million EUR | -70.08% |
| 2013 Q2 | -2.38 Million EUR | -24.52% |
| 2013 FY | - EUR | -219.98% |
| 2013 Q1 | -1.91 Million EUR | 0.0% |
| 2012 Q1 | -604.5 Thousand EUR | 0.0% |
| 2012 FY | - EUR | 61.81% |
| 2012 Q4 | -1.91 Million EUR | -217.37% |
| 2012 Q3 | -604.5 Thousand EUR | 0.0% |
| 2012 Q2 | -604.5 Thousand EUR | 0.0% |
| 2011 Q2 | -1.58 Million EUR | 0.0% |
| 2011 Q4 | -604.5 Thousand EUR | 61.88% |
| 2011 FY | - EUR | 70.54% |
| 2011 Q1 | -1.58 Million EUR | 0.0% |
| 2011 Q3 | -1.58 Million EUR | 0.0% |
| 2010 Q3 | -5.38 Million EUR | 0.0% |
| 2010 Q4 | -1.58 Million EUR | 70.53% |
| 2010 FY | - EUR | 10.57% |
| 2010 Q1 | -5.38 Million EUR | 0.0% |
| 2010 Q2 | -5.38 Million EUR | 0.0% |
| 2009 Q4 | -5.38 Million EUR | 9.67% |
| 2009 FY | - EUR | -33.16% |
| 2009 Q3 | -5.95 Million EUR | 0.0% |
| 2009 Q2 | -5.95 Million EUR | 0.0% |
| 2009 Q1 | -5.95 Million EUR | 0.0% |
| 2008 Q1 | -4.02 Million EUR | 0.0% |
| 2008 Q4 | -5.95 Million EUR | -48.13% |
| 2008 FY | - EUR | -33.31% |
| 2008 Q2 | -4.02 Million EUR | 0.0% |
| 2008 Q3 | -4.02 Million EUR | 0.0% |
| 2007 FY | - EUR | 19.19% |
| 2007 Q4 | -4.02 Million EUR | -47.91% |
| 2007 Q3 | -2.71 Million EUR | 0.0% |
| 2007 Q2 | -2.71 Million EUR | 0.0% |
| 2007 Q1 | -2.71 Million EUR | 0.0% |
| 2006 Q2 | -4.1 Million EUR | 0.0% |
| 2006 FY | - EUR | -11.12% |
| 2006 Q3 | -4.1 Million EUR | 0.0% |
| 2006 Q1 | -4.1 Million EUR | 0.0% |
| 2006 Q4 | -2.71 Million EUR | 33.69% |
| 2005 FY | - EUR | 0.0% |
| 2005 Q1 | -3.72 Million EUR | 0.0% |
| 2005 Q2 | -3.72 Million EUR | 0.0% |
| 2005 Q3 | -3.72 Million EUR | 0.0% |
| 2005 Q4 | -4.1 Million EUR | -9.93% |
| 2004 Q4 | -3.72 Million EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Redcare Pharmacy NV | 58.17 Million EUR | 120.146% |